Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selexipag. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR known ✓ | P43119 | 2/20 | 1.00 |
| ▸ | CKS1B | P61024 | 8/20 | 1.00 |
| ▸ | SKP1 | P63208 | 8/20 | 1.00 |
| ▸ | SKP2 | Q13309 | 8/20 | 1.00 |
| ▸ | CNR1 | P21554 | 4/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PTGDR | Q13258 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selexipag SCHEMBL29360518 | 1.00 | CKS1B (1.00) | CKS1BSKP1SKP2CNR1NR1I2 | |
| SCHEMBL19820816 | 0.99 | CKS1B (0.98) | CKS1BSKP1SKP2CNR1NR1I2 | |
| SCHEMBL5214497 | 0.93 | CKS1B (0.86) | CKS1BSKP1SKP2CNR1NR1I2 | |
| SCHEMBL5211279 | 0.92 | CKS1B (0.84) | CKS1BSKP1SKP2CNR1NR1I2 | |
| SCHEMBL5212176 | 0.92 | CKS1B (0.84) | CKS1BSKP1SKP2CNR1NR1I2 | |
| SCHEMBL5213604 | 0.92 | CKS1B (0.84) | CKS1BSKP1SKP2CNR1NR1I2 | |
| SCHEMBL19823428 | 0.91 | CKS1B (0.84) | CKS1BSKP1SKP2CNR1NR1I2 | |
| Selexipag SCHEMBL14477538 | 0.91 | CKS1B (0.84) | CKS1BSKP1SKP2CNR1NR1I2 | |
| SCHEMBL5211167 | 0.91 | CKS1B (0.83) | CKS1BSKP1SKP2CNR1NR1I2 | |
| SCHEMBL5210832 | 0.91 | CKS1B (0.83) | CKS1BSKP1SKP2CNR1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 480 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4331607-B1 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 2-{4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]BUTYLOXY}-N-(METHYLSULFONYL)ACETAMIDE | NIPPON SHINYAKU CO LTD (JP) | 2025-04-30 | — | — | EP | claimed |
| EP-4501404-A2 | SOLID PHARMACEUTICAL COMPOSITION CONTAINING 2-{4-[N-(5,6-DIPHENYLPYRAZIN-2-YL)-N-ISOPROPYLAMINO]BUTYLOXY}-N-(METHYLSULFONYL)ACETAMIDE | Nippon Shinyaku Co., Ltd. (JP) | 2025-02-05 | — | — | EP | claimed |
| WO-2024142718-A1 | MANUFACTURING METHOD FOR SELEXIPAG FORM I CRYSTALS | 株式会社トクヤマ | 2024-07-04 | — | — | WO | claimed |
| US-20240197724-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | NIPPON SHINYAKU CO., LTD. (JP) | 2024-06-20 | — | — | US | claimed |
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | CUORIPS INC. (JP) | 2024-03-14 | — | — | US | claimed |
| EP-4316489-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | Nippon Shinyaku Co., Ltd. (JP) | 2024-02-07 | — | — | EP | claimed |
| CN-117510418-A | Crystallization | 日本新药株式会社 | 2024-02-06 | — | — | CN | claimed |
| CN-117157075-A | Remedies for gait disorder | 日本新药株式会社 | 2023-12-01 | — | — | CN | claimed |
| CN-110430900-B | Pharmaceutical composition comprising celecoxib | 埃科特莱茵药品有限公司 | 2023-09-19 | — | — | CN | claimed |
| US-20230113077-A1 | CONTROLLED RELEASE SELEXIPAG COMPOSITION | ACTELION PHARMACEUTICALS LTD (CH) | 2023-04-13 | — | — | US | claimed |
| US-20110105518-A1 | THERAPEUTIC AGENT FOR SPINAL CANAL STENOSIS | NIPPON SHINYAKU CO., LTD (JP) | 2011-05-05 | — | — | US | claimed |
| EP-2292231-A1 | THERAPEUTIC AGENT FOR SPINAL CANAL STENOSIS | Nippon Shinyaku Co., Ltd. (JP) | 2011-03-09 | — | — | EP | claimed |
| EP-2289518-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Nippon Shinyaku Co., Ltd. (JP) | 2011-03-02 | — | — | EP | claimed |
| US-20110015211-A1 | FIBROSIS INHIBITOR | NIPPON SHINYAKU CO., LTD. (JP) | 2011-01-20 | — | — | US | claimed |
| EP-2246336-A1 | FIBROSIS INHIBITOR | Nippon Shinyaku Co., Ltd. (JP) | 2010-11-03 | — | — | EP | claimed |
| WO-2010075861-A2 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF | THROMBOLOGIC APS (DK) | 2010-07-08 | — | — | WO | claimed |
| US-7205302-B2 | Anticoagulants; antilipemic agents; cardiovascular disorders | NIPPON SHINYAKU CO., LTD. (JP) | 2007-04-17 | — | — | US | claimed |
| EP-1400518-B1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | NIPPON SHINYAKU CO LTD (JP) | 2007-01-17 | — | — | EP | claimed |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | NIPPON SHINYAKU CO., LTD. (JP) | 2004-05-27 | — | — | US | claimed |
| EP-1400518-A1 | HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES | Nippon Shinyaku Co., Ltd. (JP) | 2004-03-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015211-A1 | FIBROSIS INHIBITOR | MMP1, ARG1, MMP8 | PTGIR 373/4885CKS1B 2281/4885SKP1 3636/4885 |
| US-20230113077-A1 | CONTROLLED RELEASE SELEXIPAG COMPOSITION | MLNR, PARP9, SIRT7 | PTGIR 162/4885CKS1B 2690/4885SKP1 1723/4885 |
| US-20240197724-A1 | THERAPEUTIC AGENT FOR GAIT DISTURBANCE | MT-ND6, NLN, CLN6 | PTGIR 1787/4885CKS1B 1622/4885SKP1 2974/4885 |
| US-20110105518-A1 | THERAPEUTIC AGENT FOR SPINAL CANAL STENOSIS | NR0B1, GFRA1, NR0B2 | PTGIR 784/4885CKS1B 2826/4885SKP1 4181/4885 |
| US-20240082154-A1 | DISEASE-SITE-SPECIFIC LIPOSOMAL FORMULATION | LPAR2, PLA2R1, PTGDR2 | PTGIR 10/4885CKS1B 4048/4885SKP1 3833/4885 |
| US-20040102436-A1 | Heterocyclic compound derivatives and medicines | CNR2, CNR1, GPR55 | PTGIR 30/4885CKS1B 858/4885SKP1 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.